ADAMTS5 Modulates Breast Cancer Development as a Diagnostic Biomarker and Potential Tumour Suppressor, Regulated by BAIAP2‐AS1, CRNDE and hsa‐miR‐135b‐3p: Integrated Systems Biology and Experimental Approach
IET Systems Biology · 2025-01 · 19 (1)
DOI: 10.1049/syb2.70015 ↗Kurz gefasst
Fachartikel in der Zeitschrift IET Systems Biology, online erschienen am 05.06.2025. Verfasst von Najmeh Tavousi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Zist Fanavari Novin Biotechnology Institute, Isfahan, Iran. Hauptthemen laut MEDLINE: Breast Neoplasms, MicroRNAs, Biomarkers, Tumor, ADAMTS5 Protein. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
ADAMTS5, a member of the ADAMTS family, exhibits crucial biological roles, including protein shedding, proteolysis, and cell migration. Its relevance in breast cancer (BC) was explored through an integrative approach combining high‐throughput analyses, database validations, and experimental confirmation. ADAMTS5 expression was significantly reduced in BC samples, as verified by microarray analysis, qRT‐PCR, and public database resources. A protein–protein interaction network revealed five proteins—COL10A1, COL11A1, COMP, MMP1 and SDC1—that interact with ADAMTS5 and are primarily associated with the ECM‐receptor interaction pathway. These proteins also engage in cell cycle checkpoint signalling, emphasising their potential role in tumour progression. Survival analysis of BC samples identified a novel prognostic signature based on ADAMTS5‐related proteins. The study extended to coding and noncoding RNA interactions, identifying lncRNAs as key regulators. CRNDE acts as a ceRNA for ADAMTS5, modulating its expression via hsa‐miR‐135b‐3p. Meanwhile, BAIAP2‐AS1 interacts directly with ADAMTS5, offering another layer of regulatory control and prognostic value. These findings position ADAMTS5 as a vital player in BC biology, with its low expression linked to critical pathways and survival outcomes. The identified lncRNA‐mediated regulatory mechanisms add depth to understanding ADAMTS5's role and suggest potential targets for therapeutic development. This study underscores ADAMTS5's potential as a biomarker and its broader implications in unravelling BC molecular mechanisms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Zist Fanavari Novin Biotechnology Institute, Isfahan, Iran.
- Student Research Committee, Isfahan University of Medical Sciences, Isfahan, Iran.
- Department of Biology and Biotechnology, University of Pavia, Pavia, Italy.
ORCID-Profile: Najmeh Tavousi, Elnaz Nasiriyan, Parastoo Tabaeian, Mohammad Rezaei, Mansoureh Azadeh
Zitieren
APA
Tavousi, N., Taqizadeh, Q., Nasiriyan, E., Tabaeian, P., Rezaei, M., & Azadeh, M. (2025). ADAMTS5 Modulates Breast Cancer Development as a Diagnostic Biomarker and Potential Tumour Suppressor, Regulated by BAIAP2‐AS1, CRNDE and hsa‐miR‐135b‐3p: Integrated Systems Biology and Experimental Approach. IET Systems Biology, 19(1). https://doi.org/10.1049/syb2.70015
Vancouver
Tavousi N, Taqizadeh Q, Nasiriyan E, Tabaeian P, Rezaei M, Azadeh M. ADAMTS5 Modulates Breast Cancer Development as a Diagnostic Biomarker and Potential Tumour Suppressor, Regulated by BAIAP2‐AS1, CRNDE and hsa‐miR‐135b‐3p: Integrated Systems Biology and Experimental Approach. IET Systems Biology. 2025;19(1). doi:10.1049/syb2.70015
BibTeX
@article{Tavousi2025,
author = {Tavousi, Najmeh and Taqizadeh, Qazal and Nasiriyan, Elnaz and Tabaeian, Parastoo and Rezaei, Mohammad and Azadeh, Mansoureh},
title = {ADAMTS5 Modulates Breast Cancer Development as a Diagnostic Biomarker and Potential Tumour Suppressor, Regulated by BAIAP2‐AS1, CRNDE and hsa‐miR‐135b‐3p: Integrated Systems Biology and Experimental Approach},
journal = {IET Systems Biology},
year = {2025},
volume = {19},
number = {1},
doi = {10.1049/syb2.70015}
}
EUVIMED